PDCD1 and non-small cell lung carcinoma: During the same period, 55.3% of patients with nonsquamous NSCLC were treated with anti–PD-1/PD-L1 in combination with platinum-based chemotherapy, and 40.8% received anti–PD-1/PD-L1 monotherapy (data not shown).